(Q38996307)

8 September 2017

title

MiR-718 represses VEGF and inhibits ovarian cancer cell progression (English)

1 reference

8 September 2017

1 reference

Ruobing Leng

1

1 reference

8 September 2017

Lang Zha

series ordinal

2

1 reference

8 September 2017

Liangdan Tang

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

8 May 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

588

1 reference

8 September 2017

issue

12

1 reference

8 September 2017

page(s)

2078-2086

1 reference

MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

MiR-125b targets BCL3 and suppresses ovarian cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2014.04.040

10.1016/J.FEBSLET.2014.04.040

21 January 2018

Identifiers

DOI

1 reference

release_ixckfx3xcjevpfazfbcckfsfg4

8 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ixckfx3xcjevpfazfbcckfsfg4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference